Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of Multiple Administration of Micelle on the Suppression of Human Breast Cancer
Open Access
- 27 December 2010
- Vol. 3 (1), 61-78
- https://doi.org/10.3390/cancers3010061
Abstract
The triblock copolymer is composed of two identical hydrophilic segments: Monomethoxy poly(ethylene glycol) (mPEG) and one hydrophobic segment poly(ε‑caprolactone) (PCL); which is synthesized by coupling of mPEG-PCL-OH and mPEG‑COOH in a mild condition using dicyclohexylcarbodiimide and 4-dimethylamino pyridine. The amphiphilic block copolymer can self-assemble into nanoscopic micelles to accommodate doxorubixin (DOX) in the hydrophobic core. The physicochemical properties and in vitro tests, including cytotoxicity of the micelles, have been characterized in our previous study. In this study, DOX was encapsulated into micelles with a drug loading content of 8.5%. Confocal microscopy indicated that DOX was internalized into the cytoplasm via endocystosis. A dose-finding scheme of the polymeric micelle (placebo) showed a safe dose of PEG-PCL-PEG micelles was 71.4 mg/kg in mice. Importantly, the circulation time of DOX-loaded micelles in the plasma significantly increased compared to that of free DOX in rats. A biodistribution study displayed that plasma extravasation of DOX in liver and spleen occurred in the first four hours. Lastly, the tumor growth of human breast cancer cells in nude mice was suppressed by multiple injections (5 mg/kg, three times daily on day 0, 7 and 14) of DOX-loaded micelles as compared to multiple administrations of free DOX.Keywords
This publication has 38 references indexed in Scilit:
- Doxorubicin-Loaded Nanosized Micelles of a Star-Shaped Poly(ε-Caprolactone)-Polyphosphoester Block Co-polymer for Treatment of Human Breast CancerJournal of Biomaterials Science, Polymer Edition, 2011
- Understanding and Overcoming Major Barriers in Cancer NanomedicineNanomedicine, 2010
- Multifunctional Micellar Nanomedicine for Cancer TherapyExperimental Biology and Medicine, 2009
- Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactantJournal of Controlled Release, 2008
- Doxorubicin‐Loaded Polymeric Micelle Overcomes Multidrug Resistance of Cancer by Double‐Targeting Folate Receptor and Early Endosomal pHSmall, 2008
- Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulationsBiomedical Chromatography, 2008
- Multi-functional nanocarriers to overcome tumor drug resistanceCancer Treatment Reviews, 2008
- Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted LiposomesCancer Research, 2004
- Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2003
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerAnti-Cancer Drugs, 2003